Molecular Dosimetry of Temozolomide: Quantification of Critical Lesions, Correlation to Cell Death Responses, and Threshold Doses

Temozolomide (TMZ) is a DNA-methylating agent used in cancer chemotherapy, notably for glioblastoma multiforme (GBM), where it is applied as a front-line drug. One of the DNA alkylation products of TMZ is the minor lesion O(6)-methylguanine (O(6)MeG), which is responsible for nearly all genotoxic, c...

Descripción completa

Detalles Bibliográficos
Autores principales: Stratenwerth, Björn, Geisen, Susanne M., He, Yang, Beltzig, Lea, Sturla, Shana J., Kaina, Bernd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Small Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398175/
https://www.ncbi.nlm.nih.gov/pubmed/34253592
http://dx.doi.org/10.1158/1535-7163.MCT-21-0228

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398175/
https://www.ncbi.nlm.nih.gov/pubmed/34253592
http://dx.doi.org/10.1158/1535-7163.MCT-21-0228

Ejemplares similares